The Food and Drug Administration, under heavy criticism over its decision last month to approve Biogen's Alzheimer's drug Aduhelm, has revised the medicine's prescribing information in an effort to focus treatment to the type of patients who were included in clinical testing.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,